FDA Brief

Warning letters Drugs

FDA warning letter to

Xcel Research LLC

High riskIssued Dec 10, 2024Posted Dec 17, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.

What happened

FDA reviewed Xcel Research's website in October 2024 and found offers to sell peptide products including Retatrutide, Cagrilintide/Semaglutide, Mazdutide, Semaglutide, Survodutide, and Sermorelin. The site made claims that these products can manage weight, blood sugar, cardiovascular health, and other disease-related conditions, despite 'FOR RESEARCH USE ONLY' statements. FDA said the products are unapproved new drugs and not generally recognized as safe and effective for those uses.

What FDA found

  1. Website claims show the products are intended for human use as drugs, despite 'FOR RESEARCH USE ONLY' and 'NOT INTENDED FOR HUMAN USE' statements.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
  2. FDA said the products are not generally recognized as safe and effective for the claimed uses and are therefore 'new drugs.'

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. No FDA-approved applications are in effect for the products, so selling them across state lines violates the new-drug approval requirement.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks Xcel Research to notify it in writing within fifteen working days of steps taken to address the violations, prevent recurrence, and provide related documentation. If corrections cannot be completed in that time, the company must state why and give a completion date.

Who should pay attention

  • companies selling peptides online
  • suppliers of GLP-1-like peptides
  • buyers of research-use-only peptide products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk